Protective Effects of Intravenous Magnesium Sulfate in Stroke Patients Receiving Amiodarone: A Randomized Controlled Trial

Panahi, Yunes; Mojtahedzadeh, Mojtaba; Najafi, Atabak; Gheini, Mohammadreza; Abdollahi, Mohammad; Sharifzadeh, Mohammad; Ahmadi, Arezoo; Ganjali, Shiva; Rajaee, Seyyed Mahdi; Barreto, George E.; Sahebkar, Amirhossein

doi:10.1007/978-3-030-64872-5_28

Cited by 1 publication

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Magnesium can raise the threshold for electrical excitation in myocardial cells, slowing atrioventricular conduction, and increasing sinus node recovery times [ 38 ], particularly in the setting of use of vasoactive medications. Magnesium may reduce inflammatory markers [ 39 ], specifically IL-6, which is uniquely associated with atrial electrical remodeling [ 40 ]. It has shown promise in preventing the development of NOAF.…”

Section: Discussionmentioning

confidence: 99%

“…Critically ill patients have many risk factors for the development of NOAF including a high prevalence of hypomagnesemia [ 32 , 33 ], heightened inflammatory state [ 34 , 35 ], and frequent use of vasoactive medications [ 36 , 37 ]. Despite the potential benefit of magnesium prophylaxis in critically ill patients due to its anti-arrhythmogenic [ 38 ] and anti-inflammatory [ 39 , 40 ] properties, magnesium prophylaxis of NOAF in populations outside of cardiac surgery has not been adequately studied. Due to the lack of evidence to guide practice on the use of magnesium in a general critical care population, we performed a systematic review and meta-analysis to determine if there was a benefit for the use of magnesium therapy for the prophylaxis of NOAF in any patients outside the cardiac surgery population, including subgroups that may be found in a medical/surgical ICU to inform practice in this population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Magnesium prophylaxis of new-onset atrial fibrillation: A systematic review and meta-analysis

Curran,

Ross-White,

Sibley

2023

PLoS ONE

View full text Add to dashboard Cite

Purpose Atrial fibrillation (AF) is the most common cardiac arrhythmia in intensive care units (ICU) and is associated with increased morbidity and mortality. Magnesium prophylaxis has been shown to reduce incidence of AF in cardiac surgery patients, however, evidence outside this population is limited. The objective of this study is to summarize studies examining magnesium versus placebo in the prevention of NOAF outside the setting of cardiac surgery. Source We performed a comprehensive search of MEDLINE, EMBASE, and Cochrane Library (CENTRAL) from inception until January 3rd, 2023. We included all interventional research studies that compared magnesium to placebo and excluded case reports and post cardiac surgery patients. We conducted meta-analysis using the inverse variance method with random effects modelling. Principal findings Of the 1493 studies imported for screening, 87 full texts were assessed for eligibility and six citations, representing five randomized controlled trials (n = 4713), were included in the review, with four studies (n = 4654) included in the pooled analysis. Administration of magnesium did not significantly reduce the incidence of NOAF compared to placebo (OR 0.72, [95% CI 0.48 to 1.09]). Conclusion Use of magnesium did not reduce the incidence of NOAF, however these studies represent diverse groups and are hindered by significant bias. Further studies are necessary to determine if there is benefit to magnesium prophylaxis for NOAF in non-cardiac surgery patients.

show abstract

Section: Discussionmentioning

confidence: 99%